StockData
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. (CCCC) stock

CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/302% below fair value
$2.53−0.12 (-4.53%)

Close on Nov 17, 2026Market cap $311.25MP/E –Yield –

C4 Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

C4 Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$111.77M. For fiscal 2025 it was -$115.22M. The highest annual figure on record is -$35.45M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$115.22M–
FY2024Dec 31, 2024-$119.61M–
FY2023Dec 31, 2023-$139.03M–
FY2022Dec 31, 2022-$129.53M–
FY2021Dec 31, 2021-$82.13M–
FY2020Dec 31, 2020-$60.45M–
FY2019Dec 31, 2019-$35.45M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$26.42M–
Q1 FY2026Mar 31, 2026-$27.79M–
Q4 FY2025Dec 31, 2025-$23.15M–
Q3 FY2025Sep 30, 2025-$34.41M–
Q2 FY2025Jun 30, 2025-$28.50M–
Q1 FY2025Mar 31, 2025-$29.16M–
Q4 FY2024Dec 31, 2024-$37.71M–
Q3 FY2024Sep 30, 2024-$28.24M–
Q2 FY2024Jun 30, 2024-$21.44M–
Q1 FY2024Mar 31, 2024-$32.22M–
Q4 FY2023Dec 31, 2023-$37.43M–
Q3 FY2023Sep 30, 2023-$27.81M–
Q2 FY2023Jun 30, 2023-$37.57M–
Q1 FY2023Mar 31, 2023-$36.23M–
Q4 FY2022Dec 31, 2022-$38.29M–
Q3 FY2022Sep 30, 2022-$32.49M–
Q2 FY2022Jun 30, 2022-$27.38M–
Q1 FY2022Mar 31, 2022-$31.37M–
Q4 FY2021Dec 31, 2021-$15.26M–
Q3 FY2021Sep 30, 2021-$24.25M–
Q2 FY2021Jun 30, 2021-$22.12M–
Q1 FY2021Mar 31, 2021-$20.51M–
Q4 FY2020Dec 31, 2020-$18.90M–
Q3 FY2020Sep 30, 2020-$18.35M–
Q2 FY2020Jun 30, 2020-$10.86M–
Q1 FY2020Mar 31, 2020-$12.34M–
Q4 FY2019Dec 31, 2019-$10.50M–
Q3 FY2019Sep 30, 2019-$10.00M–

More C4 Therapeutics figures

See a number that looks wrong?